Building CAR‑T therapies with GMP‑first thinking

“We see in vivo as a much simpler and economical way to bring CAR‑Ts to patients, but it is as yet largely unproven. We think that we are bringing some solutions and helping take the field forward.”

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with Stefanos Theoharis, CEO, OneChain Immunotherapeutics, about advancing CAR‑T therapies for T cell acute lymphoblastic leukemia, designing manufacturing strategies with GMP in mind from day one, selecting the right CDMO partners, and the company's emerging in vivo CAR‑T platform.

Please enter your email to access content Read now